LncRNA EILA通过稳定环林E1蛋白来促进乳腺癌中CDK4/6抑制剂的耐药性
Zijie Cai1,2, Qianfeng Shi1,2, Yudong Li1,2
1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.
Science advances
|October 6, 2023
概括
一种新的长非编码RNA,EILA,通过稳定环林E1.1,促进乳腺癌中对CDK4/6抑制剂的耐药性. 准EILA可能会克服治疗耐药性并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 结合内分泌治疗的环素依赖性激酶4/6抑制剂 (CDK4/6i) 是晚期HR+/HER2-乳腺癌的标准.
- 获得对CDK4/6i治疗的耐药性是一个重大的临床挑战,限制了长期患者的益处.
研究的目的:
- 确定驱动乳腺癌中CDK4/6i耐药性的新机制.
- 调查环林E1相互作用的lncRNA EILA在CDK4/6i耐药性中的作用.
主要方法:
- 在CDK4/6i抗性乳腺癌细胞中研究EILA表达.
- 利用体外和体内模型来评估EILA沉默对CDK4/6i敏感性的影响.
- 阐明了EILA介导的环素E1稳定及其与FBXW7.7.的相互作用的分子机制.
主要成果:
- 在CDK4/6i耐药细胞中,EILA被上调,并通过稳定环林E1蛋白来促进耐药性.
- 在乳腺癌患者中,EILA过度表达与更快的细胞周期进展和更差的预后相关.
- 沉默EILA通过降低环素E1水平并阻止其降解来恢复对CDK4/6i治疗的敏感性.
结论:
- EILA在调节环林E1稳定性方面发挥着关键作用,并有助于CDK4/6i耐药性.
- EILA代表了治疗反应的潜在预测生物标志物,也是克服对CDK4/6抑制剂耐药性的治疗标.
相关概念视频
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:39Positive Regulator Molecules
5.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
01:23Negative Regulator Molecules
35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
02:15M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K